Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24329197 | 0.78 | CYP2A6 (0.41) | KDM4ENOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL12014830 | 0.78 | PDE10A (0.42) | NOS3NOS1NOS2ALDH1A1MAPK1 | |
| SCHEMBL17697522 | 0.77 | NOS2 (0.46) | KDM4ENOS3NOS1NOS2F12 | |
| SCHEMBL23795349 | 0.76 | GABRA1 (0.40) | NOS3NOS1NOS2AURKAALDH1A1 | |
| SCHEMBL11815604 | 0.76 | PDE4A (0.39) | KDM4ENOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL28220550 | 0.73 | KDM4E (0.45) | KDM4ENOS3NOS1NOS2PI4KA | |
| SCHEMBL22114195 | 0.73 | ATM (0.47) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL21939927 | 0.73 | SLC6A2 (0.36) | KDM4EAURKAALDH1A1HPGD | |
| SCHEMBL12070709 | 0.72 | PLAU (0.52) | KDM4ENOS3NOS1NOS2PI4KA | |
| SCHEMBL11017038 | 0.72 | POLB (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113705-A1 | IMPROVED METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | AVIDEA TECHNOLOGIES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-2935291-B1 | IRIDIUM COMPLEXES USED IN OLIGOMERS, POLYMERS OR DENDRIMERS IN ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-20150349277-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| US-20150349277-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| WO-2014094960-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-06-26 | — | — | WO | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| US-4127720-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150349277-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | KDM4E 3816/4885NOS3 3317/4885NOS1 3883/4885 |
| US-20210113705-A1 | IMPROVED METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | KDM4E 4718/4885NOS3 3115/4885NOS1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.